Venetoclax and dexamethasone for untreated AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two oral medicines (venetoclax and dexamethasone) for people with newly diagnosed AML who cannot have or choose not to have high-dose chemotherapy. The goal is to see if this gentler treatment is safe and tolerable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have been newly diagnosed with AML (a type of blood cancer).
- You have not yet received any treatment for your AML.
- You are not able to have or have chosen not to have high-dose chemotherapy (intensive induction).
- Your kidneys and liver are working well enough (checked with blood tests).
- You do not have acute promyelocytic leukemia (a specific subtype of AML).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, venetoclax and a hypomethylating agent (HMA), as the first treatment for adults with a type of leukemia called AML. The goal is to see if this combination works well and is safe for patients who have not had prior chemotherapy.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests whether adding the targeted drug venetoclax to intensive chemotherapy works better for different types of AML. It is for people aged 14 to 60 who are newly diagnosed and have not received prior treatment.
This trial tests adding venetoclax to standard chemotherapy to help people with newly diagnosed acute myeloid leukemia (AML) or high-risk MDS (MDS-EB-2) live longer and reduce cancer activity. You may benefit if you’re eligible for intensive chemotherapy and meet specific blood, organ, and treatment timing requirements.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
Hear when a new AML - Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.